These data support a prominent pro-oncogenic role of the IL-7R pathway in T-ALL, which concurs with the identification of oncogenic mutations in several IL-7R-signaling downstream molecules such as JAK1, JAK3, and STAT5B in 5–20% of T-ALL cases [43,48,143]. The gene discussed is IL7R; the disease is acute lymphoblastic leukemia.